Lpath Inc Stock News

ShockWave Medical (NASDAQ:SWAV) and Apollo Endosurgery (NASDAQ:APEN) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, dividends, analyst recommendations, earnings and profitability. Institutional & Insider Ownership 91.4% of ShockWave Medical shares are held by institutional investors. Comparatively, 64.7% []

Apollo Endosurgery, Inc. (NASDAQ:APEN) was the target of a significant decline in short interest during the month of November. As of November 15th, there was short interest totalling 301,500 shares, a decline of 34.3% from the October 31st total of 458,900 shares. Based on an average daily volume of 220,600 shares, the days-to-cover ratio is [] The post Apollo Endosurgery, Inc. (NASDAQ:APEN) Sees Significant Decline in Short Interest appeared first on ETF Daily News .

Apollo Endosurgery, Inc. (NASDAQ:APEN) was the recipient of a large decline in short interest during the month of November. As of November 15th, there was short interest totalling 301,500 shares, a decline of 34.3% from the October 31st total of 458,900 shares. Currently, 1.8% of the companys shares are sold short. Based on an average []

Geode Capital Management LLC raised its position in shares of Apollo Endosurgery, Inc. (NASDAQ:APEN) by 22.7% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 119,737 shares of the biotechnology company’s stock after purchasing an additional 22,131 shares during the […]

Related Stocks: CVRX , ATEC , BLI , STIM , BDSX , SERA , APEN , GDRX , IRTC , OPFI , OSCR , PAYO , AWH , MGI , AFIB , OCX , AXNX ,

AUSTIN, TX / ACCESSWIRE / November 12, 2021 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, to

Apollo Endosurgery, Inc. (APEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

The consensus price target hints at a 35.4% upside potential for Apollo Endosurgery, Inc. (APEN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in e

Apollo Endosurgery, Inc. (APEN) CEO Charles McKhann on Q3 2021 Results - Earnings Call Transcript

Apollo Endosurgery (NASDAQ:APEN) reported its Q3 earnings results on Monday, November 1, 2021 at 04:00 PM. Here's what investors need to know about the announcement.

Apollo Endosurgery (NASDAQ:APEN) is set to give its latest quarterly earnings report on Monday, 2021-11-01. Here's what investors need to know before the announcement.

AUSTIN, TX / ACCESSWIRE / October 27, 2021 / Apollo Endosurgery, Inc. ("Company" or "Apollo") (NASDAQ:APEN), a global leader in next-generation minimally invasive medical devices for gastrointestinal

AUSTIN, TX / ACCESSWIRE / October 15, 2021 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, announce

AUSTIN, TX / ACCESSWIRE / October 12, 2021 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, announce

AUSTIN, TX / ACCESSWIRE / October 12, 2021 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, announce